These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 30591098)

  • 1. [Research Progress of the Role of EMT in EGFR-TKIs Resistance 
of Non-small Cell Lung Cancer].
    Yu L; Huang S; Lv W; He Z; Hu J
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):907-911. PubMed ID: 30591098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
    Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Yoshida T; Song L; Bai Y; Kinose F; Li J; Ohaegbulam KC; Muñoz-Antonia T; Qu X; Eschrich S; Uramoto H; Tanaka F; Nasarre P; Gemmill RM; Roche J; Drabkin HA; Haura EB
    PLoS One; 2016; 11(1):e0147344. PubMed ID: 26789630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition.
    Wang CY; Lee MH; Kao YR; Hsiao SH; Hong SY; Wu CW
    Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):119016. PubMed ID: 33744274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
    Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
    Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
    Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
    Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
    Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK
    Cells; 2020 Dec; 9(12):. PubMed ID: 33287368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer.
    Rastogi I; Rajanna S; Webb A; Chhabra G; Foster B; Webb B; Puri N
    Biochem Biophys Res Commun; 2016 Sep; 477(4):937-944. PubMed ID: 27396618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer.
    Bronte G; Bravaccini S; Bronte E; Burgio MA; Rolfo C; Delmonte A; Crinò L
    Biol Rev Camb Philos Soc; 2018 Nov; 93(4):1735-1746. PubMed ID: 29671943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regulatory role of APE1 in epithelial-to-mesenchymal transition and in determining EGFR-TKI responsiveness in non-small-cell lung cancer.
    Yang X; Peng Y; Jiang X; Lu X; Duan W; Zhang S; Dai N; Shan J; Feng Y; Li X; Cheng Y; Yang Y; Baugh L; Tell G; Wang D; Li M
    Cancer Med; 2018 Sep; 7(9):4406-4419. PubMed ID: 30109782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Jung S; Kim DH; Choi YJ; Kim SY; Park H; Lee H; Choi CM; Sung YH; Lee JC; Rho JK
    Sci Rep; 2021 Oct; 11(1):19667. PubMed ID: 34608255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y; Wang H; He C
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.
    Suda K; Murakami I; Yu H; Kim J; Tan AC; Mizuuchi H; Rozeboom L; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    Mol Cancer Ther; 2018 Oct; 17(10):2257-2265. PubMed ID: 30049789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip.
    Tan J; Zhu L; Shi J; Zhang J; Kuang J; Guo Q; Zhu X; Chen Y; Zhou C; Gao X
    Eur J Pharm Sci; 2024 Aug; 199():106805. PubMed ID: 38763450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
    Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
    J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
    Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.